Identification of a Potent Pan-Coronaviral Main Protease Inhibitor
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00645 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Pu Chen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Alberta, Edmonton, T6G 2H7AB, Canada. Hauptthemen laut MEDLINE: Antiviral Agents, Protease Inhibitors. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Li Ka Shing Institute of Virology, University of Alberta, Canada Foundation for Innovation, NIGMS NIH HHS.
Abstract (Originalsprache)
The global impact of SARS-CoV-2 and the continued emergence of zoonotic coronaviruses underscore the urgent need for broad-spectrum antivirals for pandemic preparedness. Herein, we report AVI8122, a covalent pan-coronaviral inhibitor that targets 19 Mpros across the α, β, γ, and δ genera, encompassing bat, human, and other animal coronaviruses. AVI8122 exhibits low nanomolar potency and favorable pharmacokinetics in mice. Structural studies reveal that AVI8122 forms a covalent bond with the catalytic cysteine and maintains conserved interactions within the active sites of these Mpros. In cellulo, AVI8122 efficiently inhibited the replication of SARS-CoV-2 and its variants of concern as well as the activity of Mpros from all four genera. Furthermore, in mouse models, AVI8122 conferred dose-dependent protection against a lethal SARS-CoV-2 infection. Our findings position AVI8122 as an early lead compound and a tractable structural starting point for the development of broad-spectrum antivirals against future coronavirus spillover threats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Alberta, Edmonton, T6G 2H7AB, Canada.
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, T6G 2E1AB, Canada.
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, T6G 2E1AB, Canada.
- Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, T6G 2E1AB, Canada.
- Department of Chemistry, University of Alberta, Edmonton, T6G 2G2AB, Canada.
ORCID-Profile: Pu Chen, Elena Arutyunova, Tayla J Van Oers, Zoe Turner, Howard S Young, Bing Bai, John C Vederas, Michael A Joyce, M Joanne Lemieux
Förderung
- Li Ka Shing Institute of Virology, University of Alberta
- Canada Foundation for Innovation
- NIGMS NIH HHS
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Canadian Institutes of Health Research (CIHR)
- Government of Alberta
- GlaxoSmithKline
Zitieren
APA
Chen, P., Strunk, U., Arutyunova, E., Lu, J., Chen, S. A., Demmon, S., Maplethorpe, C., Kandadai, A. S., Shields, J., Saffran, H. A., Lamer, T., Fischer, C., Van Oers, T. J., Turner, Z., Leong, P., Iyyathurai, J., Young, H. S., Bai, B., Vederas, J. C., …, & Lemieux, M. J. (2026). Identification of a Potent Pan-Coronaviral Main Protease Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00645
Vancouver
Chen P, Strunk U, Arutyunova E, Lu J, Chen SA, Demmon S, et al. Identification of a Potent Pan-Coronaviral Main Protease Inhibitor. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00645
BibTeX
@article{Chen2026,
author = {Chen, Pu and Strunk, Ulrike and Arutyunova, Elena and Lu, Jimmy and Chen, Sizhu Amelia and Demmon, Sydney and Maplethorpe, Cassidy and Kandadai, Appan Srinivas and Shields, Justin and Saffran, Holly A and Lamer, Tess and Fischer, Conrad and Van Oers, Tayla J and Turner, Zoe and Leong, Parco and Iyyathurai, Jegan and Young, Howard S and Bai, Bing and Vederas, John C and Nieman, James A and Joyce, Michael A and Tyrrell, D Lorne and Lemieux, M Joanne},
title = {Identification of a Potent Pan-Coronaviral Main Protease Inhibitor},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00645}
}
EUVIMED